Market cap still under $300 million which isn’t bad imo given their cash position, platform potential and all of the current deals in place. Nice to hear mark give a little more color on the recent deal and how they came to him to start testing C1. If we can get into human trials, it will be big. Someone is accumulating. Hard to buy a lot of shares without jacking the price up because of the low float. Mark continues to mention sanofi which is good. He’s obviously in touch with them so hopefully something will happen with them if he continues to talk about them. Maybe we get a tbio type deal
Which would blow the doors off this stock. Sanofi has a bunch of money to spend so a few hundred million or more would be nothing to them, need to hear more on current deals. Mark continues to make mention of all these things going on. Hope to hear more soon. Need to monetize
News 
Market Data 
Discover 
